Impact investments in outstanding healthcare projects
Article25: Right to an adequate standard of living
Everyone has the right to a standard of living adequate for the health and well-being of him/herself...
The Universal Declaration of Human Rights
United Nations. December 10, 1948
in areas with clear clinical or health related unmet needs, to make a significant contribution...
to create a synergistic effect in the investment field of leveraged contributions to make a...
of exit scenarios to guarantee an expedited fruitful divestment
Meaningful investments in areas of unmet need in healhcare, coordinated to make a substantial social impact within a predefined time frame.
80%
fund capital Flagship GrowthIndustrial and healthcare infrastructure, risk-mitigated impactment investment projects
20%
fund capital BreakthroughTransformational investments in innovative projects in lifesciences, biotech and technology
Innovative and dynamic professional with +20 years of technical, entrepreneurial and leadership experience in Molecular Diagnostics and Precision Medicine.
Recent work focused on strategic advice to major global pharmaceutical and Dx companies, Investment Funds, VCs, and Governments on precision medicine strategies and on the effective integration of Dx and Rx into drug development and market adoption pathways. European Commission advisor. ASCO evaluator.
MD, PhD, MBA. Spare time devoted to collaborations with NGOs, having founded children’s NGOs in Africa and Europe. Enjoys travelling, cultural activities, music, arts, horseback riding, yoga, squash and tennis.
Biotech entrepreneur with 14+ years experience in the health & biotech sector.
Extensive international finance & legal experience (NY, USA). Spain & USA lawyer (NY State).
JD, LLM, MBA.
15+ years of experience in Life Science and 5+ years global experience in strategic consulting in the precision medicine field, including pharma and diagnostic companies, NGOs and governments.
Extensive expertise in marketing, product launch and technology scouting and connected to a global network of laboratories and healthcare professionals.
PhD
Global advisor to Pharma.
+10 yrs in R&D, investment, internationalization and commercial strategy development for the Pharma and Life Sciences sectors.
Strategic consultant for the European Commission.
PhD in Oncology, Imperial College London.
+8 years experience in Personalized Medicine and Diagnostics.
Project Officer in Major International Research Institutes.
Product and Application Specialists in a number of diagnostics technologies.
Strategic, scientific advisor, laboratory workflow management.
PhD in Biotechnologies and Oncology
September is a month with important milestones presented during ESMO and WCLC. Outstanding results from DESTINY trials paved the way for new therapeutic options and clinical standards based on Daiichi-Sankio’s conjugated MoAb ENHERTHU (trastuzumab-deruxtecan) for patients with lung, gastric and breast cancer. Impressive clinical outcomes also by IMFINZI in NSCLC (plus I/O) and in SCLC....
Inflection Point Biomedical Advisors (IPBA) provides effective strategic advice and implement hands-on, innovative projects in Precision Medicine for the pharmaceutical and diagnostics industry, investment and VC funds as well as to EU and US governmental agencies.
IPBA is a key collaborator and vital partner of Article25 Capital
